Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masato Okada

Showing results (331-340 of 443) with videos related to

Pageof 45
Sort By:
The Journal of Antibiotics|January 30, 2010
Novel antibacterial compounds specifically targeting the essential WalR response regulatorYasuhiro Gotoh, Akihiro Doi, Eiji Furuta, et al.
Journal of Cardiology|September 12, 2016
Fibrillatory pattern of dissociated venous activity after pulmonary vein isolation: Novel characteristics for remnant foci of a trigger ectopy for atrial fibrillationMasato Okada, Akio Hirata, Kazunori Kashiwase, et al.
Modern Rheumatology|December 30, 2021
SAPHO syndrome and pustulotic arthro-osteitisMitsumasa Kishimoto, Yoshinori Taniguchi, Shigeyoshi Tsuji, et al.
Life Science Alliance|September 2, 2025
Amino acid-dependent TSC2 dephosphorylation by lysosome-PP2A regulates mTORC1 signaling transductionTakanori Nakamura, Shigeyuki Nada, Masaki Matsumoto, et al.
FEBS Letters|February 28, 2003
Molecular cloning and characterization of TPP36 and its isoform TPP32, novel substrates of Abl tyrosine kinaseKiichiro Tsuchiya, Youhei Kawano, Toshiyuki Kojima, et al.
Modern Rheumatology|February 8, 2022
The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysisYoshiya Tanaka, Tatsuya Atsumi, Masato Okada, et al.
Lancet (London, England)|May 29, 2017
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trialPeter Nash, Bruce Kirkham, Masato Okada, et al.
The Journal of Rheumatology|June 17, 2015
Prevalence and Clinical Characteristics of Psoriatic Arthritis in JapanYuri Ohara, Mitsumasa Kishimoto, Naoho Takizawa, et al.
Heart and Vessels|August 3, 2021
Post-ablation left atrial function impacts long-term recurrence of atrial fibrillation after ablationTakafumi Oka, Yasushi Koyama, Koji Tanaka, et al.
Circulation Research|March 18, 2006
Cardiac ischemia activates vascular endothelial cadherin promoter in both preexisting vascular cells and bone marrow cells involved in neovascularizationNaoko Kogata, Yuji Arai, James T Pearson, et al.
Pageof 45

Showing results (331-340 of 443) with videos related to

Sort By:
Pageof 45
The Journal of Antibiotics|January 30, 2010
Novel antibacterial compounds specifically targeting the essential WalR response regulatorYasuhiro Gotoh, Akihiro Doi, Eiji Furuta, et al.
Journal of Cardiology|September 12, 2016
Fibrillatory pattern of dissociated venous activity after pulmonary vein isolation: Novel characteristics for remnant foci of a trigger ectopy for atrial fibrillationMasato Okada, Akio Hirata, Kazunori Kashiwase, et al.
Modern Rheumatology|December 30, 2021
SAPHO syndrome and pustulotic arthro-osteitisMitsumasa Kishimoto, Yoshinori Taniguchi, Shigeyoshi Tsuji, et al.
Life Science Alliance|September 2, 2025
Amino acid-dependent TSC2 dephosphorylation by lysosome-PP2A regulates mTORC1 signaling transductionTakanori Nakamura, Shigeyuki Nada, Masaki Matsumoto, et al.
FEBS Letters|February 28, 2003
Molecular cloning and characterization of TPP36 and its isoform TPP32, novel substrates of Abl tyrosine kinaseKiichiro Tsuchiya, Youhei Kawano, Toshiyuki Kojima, et al.
Modern Rheumatology|February 8, 2022
The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysisYoshiya Tanaka, Tatsuya Atsumi, Masato Okada, et al.
Lancet (London, England)|May 29, 2017
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trialPeter Nash, Bruce Kirkham, Masato Okada, et al.
The Journal of Rheumatology|June 17, 2015
Prevalence and Clinical Characteristics of Psoriatic Arthritis in JapanYuri Ohara, Mitsumasa Kishimoto, Naoho Takizawa, et al.
Heart and Vessels|August 3, 2021
Post-ablation left atrial function impacts long-term recurrence of atrial fibrillation after ablationTakafumi Oka, Yasushi Koyama, Koji Tanaka, et al.
Circulation Research|March 18, 2006
Cardiac ischemia activates vascular endothelial cadherin promoter in both preexisting vascular cells and bone marrow cells involved in neovascularizationNaoko Kogata, Yuji Arai, James T Pearson, et al.
Pageof 45